Eygeris, Y., et al. Exploring the potential of saponins as adjuvants in lipid-nanoparticle-based mRNA vaccines.
Eygeris, Y., et al. Exploring the potential of saponins as adjuvants in lipid-nanoparticle-based mRNA vaccines. Mol Ther Methods Clin Dev, 2025 May 21, 33(2):101495. PMID...
Read More
Rodrigues, K.A., et al. Vaccines combining slow release and follicle targeting of antigens increase germinal center B cell diversity and clonal expansion.
Rodrigues, K.A., et al. Vaccines combining slow release and follicle targeting of antigens increase germinal center B cell diversity and clonal expansion. Sci Transl Med,...
Read More
Taquet, M., et al. Lower risk of dementia with AS01-adjuvanted vaccination against shingles and respiratory syncytial virus infections.
Taquet, M., et al. Lower risk of dementia with AS01-adjuvanted vaccination against shingles and respiratory syncytial virus infections. NPJ Vaccines, 2025 Jun 25, 10(1):1...
Read More
Hayek, H., et al. Vaccine Adjuvants in the Immunocompromised Host: Science, Safety, and Efficacy.
Hayek, H., et al. Vaccine Adjuvants in the Immunocompromised Host: Science, Safety, and Efficacy. Transpl Infect Dis, 2025 May 19, e70053. PMID: 40387162 This comprehensi...
Read More
Hu, J., et al. Herpes simplex virus 1 fusion glycoprotein B H516P prefusion mutation had no effect on vaccine immunogenicity.
Hu, J., et al. Herpes simplex virus 1 fusion glycoprotein B H516P prefusion mutation had no effect on vaccine immunogenicity. Vaccine, 2025 May 31, 57:127241. PMID: 40354...
Read More
Shi, P., et al. Discovery of novel adjuvants: Identification of saponins from Hylomecon japonica (Thunb.) Prantl & Kündig and insights into their in vitro and in vivo activities.
Shi, P., et al. Discovery of novel adjuvants: Identification of saponins from Hylomecon japonica (Thunb.) Prantl & Kündig and insights into their in vitro and in vivo...
Read More
Lu, X., et al. Natural products targeting tumour angiogenesis.
Lu, X., et al. Natural products targeting tumour angiogenesis. Br J Pharmacol, 2025 May, 182(10):2094-2136. PMID: 37680009 This comprehensive review highlights the potent...
Read More
Alves, K., et al. Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study.
Alves, K., et al. Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: inte...
Read More